<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PORACTANT ALPHA</span><br/>(por-act'ant)<br/><span class="topboxtradename">Curosurf<br/></span><b>Classifications:</b> <span class="classification">lung surfactant</span><br/><b>Prototype: </b>Beractant<br/><b>Pregnancy Category: </b>Not applicable<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>120 mg/1.5 mL, 240 mg/3 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Lung surfactant obtained from minced porcine lungs. Endogenous pulmonary surfactant lowers the surface tension on alveoli
         surfaces during respiration, and stabilizes the alveoli against collapse at resting pressures.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Alleviates respiratory distress syndrome (RDS) in premature infants caused by deficiency of surfactant.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment (rescue) of respiratory distress syndrome in premature infants.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to porcine products or poractant alpha.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Infants born &gt;3 wk after ruptured membranes; intraventricular hemorrhage of grade III or IV; major congenital malformations;
         nosocomial infection; pretreatment of hypothermia or acidosis due to increased risk of intracranial hemorrhage.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Respiratory Distress Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intratracheal</span> 2.5 mL/kg birth weight, may repeat with 1.25 mL/kg q12h times 2 more doses if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p> 			Note: Correction of acidosis, hypotension, anemia, hypoglycemia and hypothermia is recommended prior to administration of poractant
         alfa. 		
      </p><span class="adminroutetype">Intratracheal</span><br/><ul>
<li>Warm vial slowly to room temperature; gently turn upside down to form uniform suspension, but do <small>NOT</small> shake.
         </li>
<li>Withdraw slowly the entire contents of a vial (concentration equals 80 mg/mL) into a 3 or 5 mL syringe through a large gauge
            (&gt;20 gauge) needle.
         </li>
<li>Attach a 5 French catheter, precut to 8 cm, to the syringe.</li>
<li>Fill the catheter with poractant alfa and discard excess through the catheter so that only the total dose to be given remains
            in the syringe.
         </li>
<li>Refer to specific instruction provided by manufacturer for proper dosing technique. Follow instructions carefully regarding
            installation of drug and ventilation of infant. Note that catheter tip should not extend beyond distal tip of endotracheal
            tube.
         </li>
<li>Store refrigerated at 2°8° C (36°46° F) and protect from light. Do not shake vials. Do not
            warm to room temperature and return to refrigeration more than once.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, hypotension. <span class="typehead">Respiratory:</span> Intratracheal tube blockage, oxygen desaturation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Stop administration of poractant alfa and take appropriate measures if any of the following occur: Transient episodes of bradycardia,
            decreased oxygen saturation, reflux of poractant alfa into endotracheal tube, or airway obstruction. Dosing may resume after
            stabilization.
         </li>
<li>Do not suction airway for 1 h after poractant alfa instillation unless there is significant airway obstruction.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>